Clinical Trial Update: Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of bortezomib and flavopiridol in patients with recurrent or refractory indolent B-cell neoplasms, including various …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Nodal Marginal Zone Lymphoma
• Plasma Cell Myeloma
• Splenic Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Flavopiridol (alvocidib) (alvocidib)
• Velcade (bortezomib) (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma | Phase 1 | Status: COMPLETED